Какова цена за Solasia Pharma K.K. (4597)

Цена за Solasia Pharma K.K. (4597) Это $0.20877985

Какова рыночная капитализация для Solasia Pharma K.K. (4597)

Рыночная капитализация для Solasia Pharma K.K. (4597) Это $57.00M

Solasia Pharma K.K. (4597) Операционная маржа

Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.

Год	Операционная маржа	Изменить
Недостаточно данных для указанных дат.

Год

Операционная маржа

Изменить

Недостаточно данных для указанных дат.

Компания	Операционная маржа	Разница в операционной марже	Страна
MERCK Kommanditgesellschaft auf Aktien MER.SW	0.00%	-	DE
Merck KGaA MRK.DE	0.00%	-	DE
Takeda Pharmaceutical Company Limited 4502.T	0.00%	-	JP
Galderma Group AG GALD.SW	0.00%	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	22.93%	-	IN

Компания

Операционная маржа

Разница в операционной марже

Страна